Tamoxifen

Confirm delete?

Tamoxifen

Zoom

Cat No: 27190

Biochemicals - Analytical Standards

Tamoxifen (Item No. 27190) is an analytical reference standard categorized as a selective estrogen receptor modulator (SERM).{51126} Formulations containing tamoxifen have been used by bodybuilders to prevent gynecomastia associated with anabolic ster...

This article is not for sale online.
Contact us for more information about this article.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

                                            Technical Warning: Bertin Technologies restricts the sale of this product to licensed controlled substance laboratories and qualified academic research institutions. Please contact us for further details.
                    

                        Special Advice: Please check regulation status before ordering; additionel fees can apply. 
                    

Synonyms:

2-[4-[(1Z)-1,2-diphenyl-1-buten-1-yl]phenoxy]-N,N-dimethyl-ethanamine

Correlated keywords:

ICI 47699 ICI47699 Novaldex

Product Overview:
Tamoxifen (Item No. 27190) is an analytical reference standard categorized as a selective estrogen receptor modulator (SERM).{51126} Formulations containing tamoxifen have been used by bodybuilders to prevent gynecomastia associated with anabolic steroid use.{51127} Tamoxifen has been detected as an adverse analytical finding (AAF) during anti-doping testing.{48164} This product is intended for use in analytical forensic applications. This product is also available as a general research tool (Item Nos. 13258
11629).

Size	25 mg
Shipping	dry ice
CAS Number	10540-29-1
Molecular Formula	C₂₆H₂₉NO
SMILES	CC/C(C1=CC=CC=C1)=C(C2=CC=CC=C2)/C3=CC=C(OCCN(C)C)C=C3
Molecular Weight	371,5
Formulation	A crystalline solid
Purity	≥95%
Custom Code	3822.19
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.